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Background: Acute respiratory failure (ARF) remains the leading reason for intensive care unit (ICU) admission of
immunocompromised patients. In the most severe cases, high-flow oxygen therapy may fail to ensure adequate gas
exchange, and mechanical ventilation (MV) must be used. This scenario is associated with high mortality rates of 40 to
60%, depending on the cause of ARF and type of immune deficiency. The use of non-invasive ventilation (NIV) in this
situation has been criticized as potentially delaying the initiation of optimal treatment. In contrast, early NIV used
prophylactically in patients with ARF who do not meet the criteria for invasive MV (IMV) may obviate the need for IMV,
thereby decreasing the morbidity and mortality rates. We aim to demonstrate that a management strategy including early
NIV decreases 28-day mortality rates compared to oxygen therapy alone in immunocompromised patients with ARF.
Methods/Design: This is a multicenter parallel-group randomized controlled trial comparing early NIV to oxygen therapy
alone in immunocompromised patients with ARF. All immunocompromised adult patients admitted to admission for ARF
are eligible for randomization. Patient with ARF onset more than 72 hours earlier or ARF related to cardiogenic pulmonary
edema or hypercapnia, or with a need for immediate endotracheal intubation or other organ failure are not eligible.
After inclusion patient are allocated to receive early NIV (intervention arm) or oxygen therapy only (control arm).
We plan to enroll 374 patients in 29 ICUs. An interim analysis is planned after the inclusion of 187 patients. The main
objective is to demonstrate early NIV increases survival as compared to oxygen therapy alone. Other outcomes include
the need of IMV, organ failure evolution, nosocomial infections rate, 6 months survival.
Discussion: This study is expected to demonstrate an improved 28-day survival in immunocompromised patients
managed with early NIV.
Trial registration: Registration number: Clinicaltrials.gov NCT01915719. Registered on 26 July 2013.
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Acute respiratory failure (ARF) in immunocompromised
patients is both common and severe [1]. ARF is the leading
cause of ICU admission in patients with hematological or
solid malignancies. The most recent studies have found
mortality rates of nearly 50% in this population [1-3]. Mor-
tality rates are highest in patients with severe respiratory
distress requiring invasive mechanical ventilation (IMV). In
this situation, mortality can reach 40% in organ transplant
recipients and patients receiving immunosuppressive treat-
ments [4], and 60% in patients with hematological or solid
malignancies [1-3].
Noninvasive ventilation (NIV) via a mask was intro-
duced in the 1990s with the primary goal of decreasing
the need for IMV and the rate of IMV-related complica-
tions. NIV has been chiefly evaluated in two indications:
(a) as an alternative to IMV in patients with severe ARF
meeting criteria for IMV, and (b) as a means of avoiding
IMV in patients with ARF who do not meet criteria for
IMV. The use of NIV in patients with severe ARF has
been criticized, as the failure rate is nearly 50% among
immunocompromised patients and excess mortality oc-
curs among patients who receive delayed IMV [5-7].
Some studies even found improved survival after early
IMV [5,6,8]. NIV is an accepted treatment when criteria
for IMV are not met, although the underlying level of
evidence is low [9-12]. A single randomized trial in 52
patients established that early NIV improved survival in
immunocompromised patients [11]. However, this studyFigure 1 Outcomes associated with the in-ICU use of non-invasive venthas three major flaws: (a) the patients were recruited at
a single center; (b) the mortality rate among patients
managed with IMV was 90%, which is considerably
higher than current rates; and (c) acute illness severity
varied across patients, with some patients apparently
meeting criteria for IMV at baseline and others having
no criteria for severe ARF. Nevertheless, the beneficial
effect of NIV on survival was impressive: mortality was
81% without NIV and 50% with NIV. The result of an
Italian study of 40 solid organ transplant recipients sup-
ports the beneficial effect of postoperative NIV on sur-
vival [12].
Figure 1 illustrates these data by showing the results of
studies reporting outcomes of immunocompromised pa-
tients with ARF. We compared hospital mortality in pa-
tients managed with oxygen alone and in patients given
NIV.
This forest plot figure represents cohort studies or trials
reporting both patients receiving oxygen or NIV. Studies
are presented with first author name, year of publication
(number of patients treated with oxygen only and number
of patients receiving NIV and oxygen). Odd Ratio (OR
and [95% CI] comparing mortality associated with the use
of NIV.
These studies include: two randomized ICU trials com-
paring two strategies for managing immunocompromised
patients with ARF (Antonelli and Hilbert) [11,12]; a 2004
prospective nonrandomized trial evaluating the impact of
ARF in patients with hematological or solid malignanciesilation in immunocompromised patients. Adapted from Azoulay E, 13.
Lemiale et al. Trials 2014, 15:372 Page 3 of 8
http://www.trialsjournal.com/content/15/1/372(Azoulay) [1]; an ICU study in non-intubated patients
with ARF randomized to two different diagnostic strat-
egies (Azoulay) [13]; a retrospective study of ICU patients
with ARF managed with oxygen only or NIV (Depuydt)
[14]; and a 2011 multicenter Italian observational ICU
study of patients with hematological malignancies and
ARF (Gristina) [15].
This literature review shows no difference in mortality
rates between patients managed with oxygen only and
those given NIV. However, none of these studies pro-
vides a sufficient level of evidence. In addition, patients
in whom ARF was combined with other organ failures
were not separated from those with isolated ARF. This is
an important point, as the risk of mortality is known to
increase with the number of organ failures and the se-
verity of the ARF. Overall, these studies suggest that
NIV may be useful as a prophylactic treatment to obvi-
ate the need for IMV. In contrast, the use of NIV as an
alternative to IMV in patients with severe ARF seems to
adversely impact survival.
We have planned a multicenter randomized controlled
trial in immunocompromised patients with ARF. This trial
will be carried out in 29 specialized ICUs in France and
Belgium (in teaching hospitals, community hospitals, and
national cancer network hospitals) with high admission
rates of immunocompromised patients. The study object-
ive is to demonstrate that incorporating early NIV into
the management strategy for patients with ARF who do
not meet criteria for IMV improves survival compared to
oxygen only.
Methods/Design
The IVNIctus trial is a prospective, multicenter, open-
label, randomized controlled trial comparing a manage-
ment strategy including early NIV with oxygen alone in
immunocompromised patients admitted to ICU with
ARF. Early NIV is defined as NIV treatment for patients
with ARF who are without any other organ failure or in-
tubation criteria (intubation criteria would be described
further (in patient management bias paragrah)).
The study hypothesis is that early NIV decreases mortal-
ity in immunocompromised patients requiring ICU admis-
sion for ARF. The primary evaluation criterion is survival
on day 28 after randomization. Secondary evaluation cri-
teria are proportion of patients treated with IMV in each
group, number of organ failures (Sequential Organ Failure
Assessment score) 72 hours after randomization in each
group, invasive mechanical ventilation duration and ICU
stay length in each group, patient comfort in each group,
frequency of nosocomial infections in each group, survival
at six months after randomization.
The primary study objective is to demonstrate that in
immunocompromised patients admitted to the ICU
with ARF, a management strategy including early NIVimproves 28-day mortality compared to high-flow oxy-
gen without NIV.Ethics
The study was approved by the local independent ethic
committee (Comite de protection des personnes CPP Ile
de France IV, Saint Louis on 21 May 2012, number
2012/11SC), the French health authorities (AFSSAPS)
on 11 5 2011, number EudraCT 2011-A00591-40. The
University Hospital of Paris (AP-HP) is the sponsor of
the trial. Informed consent will be obtained from each
participant.Eligibility criteria
Only patients meeting all inclusion criteria may be in-
cluded. Inclusion criteria are as follows: age >18 years; ICU
admission; immune deficiency due to any cause (solid
organ transplantation, hematological or solid malignancy
under treatment or in remission for less than five years, or
immunosuppressive treatment defined as corticosteroid
therapy (1 mg/Kg/day prednisone equivalent or corticoster-
oid therapy for longer than one month) or use of another
immunosuppressant drug (in a high dosage or for longer
than one month); ARF (other than during the postop-
erative period after cancer surgery) defined as hypox-
emia <60 mmHg on room air and/or clinical evidence
of respiratory distress (intercostal recession or polyp-
nea >30/min or dyspnea at rest); and onset of ARF
within the last 72 hours.
Patients meeting any of the following exclusion criteria
will be excluded from the study: hypercapnia >50 mmHg or
greater than 10 mmHg PaCO2 increase after oxygen therapy
initiation, requirement for immediate IMV, probable cardio-
genic acute pulmonary edema, requirement for vasoactive
therapy (epinephrine or norepinephrine >0.3 μg/Kg/min),
impaired consciousness (Glasgow Coma Scale score <13),
do-not-intubate decision, long-term oxygen therapy, refusal
of the patient or family to provide consent to the study, on-
going myocardial infarction or acute coronary syndrome,
pregnancy or breastfeeding or absence of coverage by the
French statutory health insurance system.Description of the study methodology
Study arms
The control group will consist of patients included in
the study and allocated at random to the arm managed
with oxygen but no NIV. In patients requiring intub-
ation, use of NIV to secure the procedure is allowed.
The intervention group will consist of patients included
in the study and allocated at random to the arm man-
aged with one hour NIV sessions in addition to oxygen.
A total of six hours is required on the first day.
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All 29 recruiting ICUs (Additional file 1: Table S1) have
considerable experience and expertise in the manage-
ment of immunocompromised patients. The 29 ICUs
participating in the study each admit 50 to 200 immuno-
compromised patients per year, including the 10 to 20%
who meet IVNIctus trial eligibility criteria. Consecutive
patients admitted to these ICUs and meeting all the in-
clusion criteria and none of the exclusion criteria will be
included into the trial.
Randomization and study treatment
Eligible patients will be randomly assigned, in a 1:1 ratio, to
one of the two treatment arms. Randomization will occur ei-
ther at ICU admission or when the eligibility criteria are
met if the patient was admitted for a reason other than
ARF. Randomization will be performed via the website
telemedicine cleanweb.aphp. After having completed the
randomization webpage, the investigator will receive the
treatment arm designation. Time zero will be defined by
randomization time. Randomization will be stratified by cen-
ter, oxygen flow rate at randomization (>or ≤9 L/min), and
reason of immunosuppression (oncologic and hematologic
malignancy or immunosuppressed treatment and solid
organ transplantation). All the data will be notified in an e-
CRF on the website telemedecine cleanweb.aphp.
In the early NIV group (intervention group), NIV ses-
sions will be administered throughout the 24-hour cycle,
with oxygen therapy sessions in the intervals, the objective
being to maintain SpO2 > 92%. NIV would be given for at
least six out of 24 hours during the first 24 hours. In the
oxygen-only group (control group), continuous oxygen
therapy will be provided to maintain SpO2 > 92%.
Treatments and procedures allowed during the trial
Bronchoalveolar lavage
BAL may be performed under NIV in both groups if re-
quired by the patient’s condition. The efficacy and safetyFigure 2 Study diagram. ARF, acute respiratory failure; NIV non-invasive vof an NIV session used to perform bronchoscopy have
been evaluated previously [16]. NIV duration and parame-
ters will be recorded in the patient’s case report form.Preoxygenation before intubation
This technique consisting in a NIV session immediately
before endotracheal intubation has been shown to de-
crease the decline in oxygen saturation during intubation
[17]. It may be used in both groups.Intravenous treatments
Participation in the trial does not result in any restric-
tions in the use of specific treatments required by the
patient’s underlying disease and/or ARF.Detailed description of the conduct of the study
Figure 2 shows a diagram of the study procedures.
Table 1 summarizes the clinical and laboratory test per-
formed throughout the study.Evaluation at study inclusion (T0)
The evaluation at study inclusion will consist of clinical
characteristics of the patient, underlying disease, disease
responsible for ARF, and investigations usually performed
at ICU admission of immunocompromised patients with
ARF.Evaluations during study participation
Evaluations performed during study participation will con-
sist of respiratory characteristics (respiratory rate, SpO2,
oxygen flow or FiO2) every hour within the first 24 hours;
data to assess the disease course on day 1, 2, 3, 4, 5, 6, 7,
14, and 28 (the worst value will be recorded); clinical data;
results of investigations; and data on NIV tolerance and
efficacy.entilation.
Table 1 Clinical and laboratory data
Clinical data Laboratory data
To: randomization Underlying disease
ARF characteristics
First 24 hours Respiratory rate, SpO2, oxygen flow or FiO2
Day1 to Day7, Day14, Day28 Respiratory data SOFA score
Course of respiratory and other organ failure
Suspected diagnosis every day
Tolerance of NIV in NIV group






SpO2: oxygen pulse saturation; FiO2: inspired oxygen fraction; SOFA: Sequential Organ Failure Assessment; ARF: acute respiratory failure; NIV non-invasive
ventilation, T0: time of randomization.
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Evaluations performed at the end of study participation will
consist of mortality on day 28, ICU length of stay, hospital
length of stay, time on IMV, and mortality on day 180.Bias minimization strategies
Recruitment bias
Before randomization, no patients will receive humidified
high-flow oxygenation. Severity of ARF will be only assessed
with the oxygen flow need at randomization, through Ven-
turi mask or nasal cannula. After randomization, patients
will receive a humidified high-flow cannula according phys-
ician. Humidified high-flow cannula use will be recorded
and analyzed.
We will include only patients with ARF but no circu-
latory failure at baseline (defined by the need of vaso-
pressor over 0.3 μ g/Kg/min), to obtain a population of
patients who have severe disease but do not meet the
criteria for IMV. We will include consecutive immuno-
compromised patients, with no restrictions based on
type of disease or treatment, in order the replicate usual
ICU practice. Patients in whom HIV infection is the
only cause of immunodeficiency will not be included
since recent data show differences in outcomes between
HIV-infected patients and patients with other causes of
immune deficiency. HIV-infected patients with other
immunocompromised disease will be included.Patient management bias
We will use predefined NIV parameters, oxygen therapy
parameters, and IMV criteria to standardize patient
management.Non-invasive ventilation parameters
We will use the NIV settings recommended for the man-
agement of ARF, in pressure support ventilation. The
mask most appropriate for the patient will be selected and
adjusted to minimize leakage and pressure points. The
level of inspiratory assistance will be increased gradually
to obtain a tidal volume (VT) of 7 to 10 mL/Kg with a re-
spiratory rate (RR) <25/min. The positive expiratory air-
way pressure will be increased from 2 to 10 cm H2O to
obtain a FiO2 < 65%. The FiO2 value will be set to keep
SpO2 > 90%. The inspiratory trigger will be set at the low-
est possible value. The physician in charge of the patient
will check that asynchronous cycles are kept to a mini-
mum (number of asynchronous cycles/total number of cy-
cles <10%). The ventilatory settings will be chosen based
on continuous SpO2 monitoring and arterial blood gas
values. NIV will be used for at least six hours within
24 hours for two days, in sessions of at least 30 to 45 mi-
nutes, with oxygen therapy in the intervals.
Criteria for weaning off NIV are as follows: resolution of
the signs of respiratory distress, RR <25/min between NIV
sessions, P/F >200 for 24 hours, or the patient refuses NIV
and does not meet the criteria for IMV. In patients requir-
ing NIV for longer than 12 out of 24 hours or over more
than five days, the need for IMV should be evaluated and
the level of NIV use considered excessive.
Oxygen parameters
The oxygen flow rate delivered through a mask will be
set to maintain SpO2 > 90%. The choice of the oxygen
therapy system will be at the discretion of the physician.
For patients receiving oxygen through a mask, FIO2
will be estimated according to the oxygen delivery sys-
tem and oxygen flow.
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The criteria for IMV are: severe hemodynamic instability
(norepinephrine or epinephrine >0.5 μ g/Kg/min), cardio-
respiratory arrest, ongoing myocardial infarction, severe
encephalopathy (Glasgow Coma Scale score <11), severe
airway secretion retention, worsening of respiratory dis-
tress (SpO2 < 92% or RR >40/min) regardless of the oxy-
gen flow rate or use of accessory muscles of respiration,
inability to maintain PaO2 > 65 mmHg with FiO2 > 0.6, de-
pendency on NIV with inability to remain off NIV for lon-
ger than two hours, or >50% increase in the time on NIV
from one day to the next (for example, six hours of NIV
on D1 followed by more than nine hours on D2).
End of the trial
Each patient will be in the trial for six months. Premature
study withdrawal will be considered if one of the following
occurs: death within the first 28 days, or if requested by
the patient or next of kin. Patients withdrawn prematurely
from the trial should undergo the procedures scheduled
for the last trial visit, to the extent possible. Furthermore,
the reason for premature trial withdrawal must be re-
corded both in the case-report form and in the source
document.
Statistical analysis
The analysis will be performed according to the intention-
to-treat approach. We will use the chi-square test to com-
pare 28-day mortality rates in the group managed with
oxygen only and in the group managed with oxygen and
early NIV. Randomization will be stratified on the under-
lying disease (hematological or solid malignancy versus
other) and on ARF severity as assessed by the baseline
oxygen flow rate (≤9 L /min versus >9 L/min to obtain
SpO2 > 95% and/or resolution of the signs of respiratory
distress). We will test for an interaction between the treat-
ment effect and the underlying disease. If such an inter-
action is found, we will use the chi-square test to look for
a treatment effect within the stratification subgroups.
We will correct for the multiple comparisons using the
Bonferroni test (error of first order 0.025). Similarly, we
will look for an interaction between the treatment effect
and baseline ARF severity. If such an interaction is found,
we will use the chi-square test to look for a treatment ef-
fect within the stratification subgroups. We will correct
for the multiple comparisons using the Bonferroni test
(error of first order 0.025).
For the secondary evaluation criteria, we will use the chi-
square test to compare the proportions of patients with
treatment failure (defined by the need of IMV), and noso-
comial infection in the two treatment arms. The procedure
described above for potential subgroup analyses of the pri-
mary evaluation criterion will be used for these secondary
evaluation criteria. Wilcoxon’s test will be performed tocompare the number of organ failures (SOFA score) be-
tween the two arms 72 hours after study inclusion. Median
hospital and ICU length of stay will be compared between
the two arms using the Kaplan-Meier estimator, with dis-
charge alive as the event of interest and death as the cen-
soring event. Time on invasive mechanical ventilation will
be compared between the two arms using the log-rank test.
Sample size estimation
Based on previous studies in the field and on evidence
of declining mortality rates over the last decade among
ICU patients with hematological or solid malignancies
[12,13,18,19], we expect 28-day mortality rates of 20%
in the early NIV arm and 35% in the oxygen-only arm.
With alpha set at 0.05, 90% power, and the chi-square
test, 187 patients are needed in each arm, totalling 374
patients in all. A single interim analysis to assess super-
iority is scheduled. The interim analysis will take place
after inclusion of half the patients (n = 187). The criteria
for premature study discontinuation based on the re-
sults of this single interim analysis will be those defined
by O’Brien and Fleming [20]. All tests will be two-sided.
The statistical analysis will be performed using SAS
9.1.3 (SAS, Inc., Cary, NC, USA) (or a more recent ver-
sion) or R.2.15.2 (R foundation for statistical computing,
Vienna, Austria). (or a more recent version).
Provisional time table
Based on the recruitment rates in the TRIAL-OH study
[21] of consecutive hematology patients admitted to the
same ICUs (appendix 4, study ongoing), the 30% propor-
tion of patients with ARF who were not intubated at ICU
admission in the same study, and the admission rate of
immunocompromised patients in the study centers, re-
cruitment is expected to last approximately 30 months.
The Data and Safety Monitoring Committee will meet
regularly to review adverse events recorded during the
trial. The overall data analysis will be performed under the
responsibility of Professor Chevret and Dr Resche-Rigon
at the Biostatistics Department of the Saint-Louis Teach-
ing Hospital, Paris, France.
Data and Safety Monitoring Committee
An independent data and safety monitoring committee
will be established. This committee will have three mem-
bers: Professor S Jaber (Saint-Éloi teaching hospital,
Montpellier, France)), Dr CE Luyt (Pitié Salpêtrière,
teatching hospital Paris France), and Professor B Maitre
(Henri Mondor teatching hospital, Crétei, Francel).
The mission of the Data and Safety Monitoring Com-
mittee consists of monitoring the safety data and provid-
ing the study sponsor with recommendations about
whether the trial should continue as planned, prolonged,
or stopped prematurely. It will also be responsible for
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periority scheduled to occur after the inclusion of half of
the patients (N = 187). The criteria defined by O’Brien and
Fleming [20] will be used to determine whether the results
of this interim analysis warrant premature discontinuation
of the trial.
Discussion
ARF remains the most frequent and challenging life-
threatening event in patients with hematological
malignancies [1,5-7,14,18]. In patients with prolonged
neutropenia (acute leukemia or bone marrow tranplant
recipients), respiratory events occur in up to half of
cases, of which a further half are complicated by ARF
[22]. Despite a recent improvement in survival, IMV re-
mains associated with high mortality in immunocom-
promised patients with ARF [21-24]. NIV has been
associated with an increase survival for these patients,
in an era when IMV was associated with a mortality rate
of over 80% [9,11]. In recent studies, mortality after in-
tubation was 60% in hematological patients and 40% in
immunocompromised patients [5,13,19,21]. In that set-
ting, appropriate management of the patients with ARF
became uncertain.
Moreover, a crucial point is the difference between
early and late NIV. Early NIV is used in patients who do
not meet criteria for IMV. In contrast, late NIV is given
as an alternative to IMV. Several recent studies found
higher mortality rates among patients who failed NIV
than among patients managed with first-line IMV [5,19].
In addition, in recent years outcomes have improved
among immunocompromised patients admitted to the
ICU, including those managed with IMV [5,7,19,21].
This improvement is ascribable not only to better pa-
tient selection for ICU admission, but also to better
overall management of the underlying disease and ARF.
Most of the studies evaluated NIV without really con-
trolling time between ARF onset to NIV implementa-
tion, without taking into account ARF etiology, and/or
without taking into account the presence of associated
organ dysfunction at the time of NIV initiation. As a
consequence, prophylactic NIV (in patients with hypox-
emia but no respiratory distress) and curative (patients
with respiratory distress needing ventilatory support)
were lumped together.
We expect this trial to assess a management strategy
including early NIV and to identify risk factors for IMV
among immunocompromised patients with ARF.
Trial status
The trail is currently recruiting patients. Inclusion started
on 1 September 2013 and the number of included patients
so far is 162. The estimated length of inclusion time is
30 months.Additional file
Additional file 1: Table S1. List of investigators involved in the study.
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